Answer

Drivers of Scent recovery, 2H evolution (Fine Fragrance & Consumer Fragrance), and 2027 R&D plan

1) What are the drivers of Scent’s recovery?

A. Better R&D capability plus rebuilding the innovation pipeline

Management links the Scent recovery to a significant improvement in R&D execution and the quality of the molecule/delivery-system pipeline. They state that ~2.5 years ago the R&D pipeline was “not what it should have been” and they were “falling behind,” while today they have a “very strong R&D capability,” a strong R&D team, “great perfumers,” and a pipeline of “molecules as well as delivery systems.” ¹

This matters because they explicitly describe Scent’s recovery plan as balancing initiatives such as investing in R&D and growing market share back. ²

B. Volume growth and productivity improvements supporting profitability

The Scent segment’s recovery is also reflected in profitability improvement, which management attributes to volume growth and productivity gains. ³ In the quarter, they report Scent segment sales up 8% and Scent EBITDA up 5% to $134 million, with volume growth and productivity gains as primary drivers. ³

C. Fragrance Ingredients rebound (and then normalization toward higher-value inputs)

Although your question is about the Scent recovery and specifically Fine/Consumer Fragrance evolution, management also calls out Fragrance Ingredients as a key driver of Scent performance in the period. They report that Fragrance Ingredients grew “north of 20%” and that Q2 performance benefited from a difficult prior-year comp (down 10% or more). ⁴

They also explain that the business used the synthetics portfolio to capture more sales amid macroeconomic conditions and supply chain disruptions plus higher Brent crude prices, but they expect normalization: as things settle down, growth should shift toward higher value-added ingredients vs. traditional synthetics. ⁴

D. Fine Fragrance execution amid Middle East uncertainty

For Fine Fragrance specifically, management credits recovery to active management of uncertainty/volatility in the Middle East. They expected Fine Fragrance growth to be down mid-single digits but it finished slightly positive, and they say they “managed the challenges in the Middle East.” ⁴

2) How will Fine Fragrance and Consumer Fragrance evolve in the second half?

Management provided a mid-level growth-rate framework for the second half and a narrative on normalization.

Fine Fragrance (second half trajectory)

Q3 expected softer, Q4 stronger: management indicates “Fine Fragrance… a little bit softer in Q3, but a stronger Q4,” targeting mid-single-digit range on a second-half basis. ⁵
Normalization after Middle East volatility + comp effects: they frame the recovery timing as factoring a softer Q3 because Q3 last year grew ~20%, which is a “big comp,” while they expect “recovery” to show up as we get to Q4 overall. ⁴

Consumer Fragrance (second half trajectory)

Low single-digit evolution with normalization after a strong Q2: management states Consumer Fragrance is “in that low single-digit range”; after a good Q2 at a “high single-digit number,” they expect it to “normalize… to kind of a low single-digit number” on a go-forward basis. ⁵
Strategic R&D and go-to-market rebuild to drive market share: they attribute the ongoing recovery effort to the team’s work to rebuild the R&D capability and go-to-market approach with customers and to drive market share gains. ⁵
Supportive recent performance into the quarter (baseline): they also report that in the quarter Consumer Fragrance increased high single digits and Fine Fragrance grew low single digits inclusive of Middle East impact. ³

Fragrance Ingredients normalization (important context for “Scent” even though not asked)

Because Scent segment performance depends on multiple sub-components, management notes:

Fragrance Ingredients “very strong” in Q2 and they expect it to normalize going forward.
Specifically, they say Fragrance Ingredients will be slightly under pressure year-over-year to calibrate normalization. ⁵
They also reiterate that the normalization is tied to a shift back toward higher-value-added ingredients vs. traditional synthetics. ⁴

3) Plan for R&D to support 2027

The excerpts describe the direction and status of the R&D plan more than a detailed program budget or milestones, but several elements are clear.

A. Fix the pipeline quality and capability gap (already executed progress)

Management states that the R&D pipeline has improved materially from the earlier shortfall:

Pipeline gap recognized ~2.5 years ago (not what it should be; falling behind). ¹
Now “very strong” R&D capability with leading-edge new Fine/Consumer fragrances and a strong pipeline of molecules and delivery systems. ¹

This is the foundation for supporting 2027 because it targets the ability to generate new fragrance propositions across Fine and Consumer categories.

B. “Higher-value natural products” shift is underway and expected to build into next years (leading into 2027)

While this statement is in the context of Fragrance Ingredients, management connects it to future competitive position (which is relevant to Scent’s multi-year recovery and innovation strategy):

They say there is a shift to higher-value natural products underway, which will take more time and they do not expect it to fully play out in the second half of this year. ⁵
They add that as we go into next year and the year after, they believe they’ll have a really strong competitive position. ⁵

If you translate that forward within their messaging, it indicates the strategy is not just near-term stabilization but positioning that should mature across the “next year and the year after” window—consistent with strengthening performance into 2027.

C. Reinvestment/innovation cycle as a long-term Remainco principle

Management explicitly ties reinvestment in innovation to a self-reinforcing loop:

They emphasize that % of sales in R&D is in the 8% to 9% range and that they must critically continue to reinvest because it sets them apart, improves growth rates, and helps expand margin while continuing reinvestment (“circle”). ⁶
They reinforce that innovation matters as a pillar of the Remainco strategy going forward. ⁶

D. Scent-specific leadership emphasis on R&D execution and perfumer-driven innovation

Management points to the leadership structure and the talent/perfumer depth supporting R&D:

They describe the R&D team and perfumers as developing “absolutely leading-edge” new Fine and Consumer fragrances, backed by molecules and delivery systems. ¹
They also characterize Scent as having strong leadership and teamwork across Fine Fragrance, Consumer Fragrance, Fragrance Ingredients, and R&D. ¹

Bottom line summary

Drivers of recovery: improved R&D capability and pipeline, execution through Middle East volatility, and commercial execution showing up as Scent sales +8% and EBITDA +5% driven by volume growth and productivity gains, alongside a Fragrance Ingredients rebound that will later normalize. ¹⁴³⁵
Second half evolution: Fine Fragrance is expected softer in Q3, stronger in Q4 with mid-single-digit growth in 2H, after factoring Middle East volatility and a ~20% Q3 prior-year comp; Consumer Fragrance should normalize from a high-single-digit Q2 toward low-single-digit on a go-forward basis, supported by rebuilding R&D capability and customer go-to-market to regain share. ⁵⁴
R&D plan for 2027: management’s plan is anchored in (1) already improved pipeline quality and perfumer-led innovation capability, (2) ongoing multi-year shift toward more value-added ingredient/product positioning (with maturation across “next year and the year after”), and (3) maintaining sustained R&D intensity (8%–9% of sales) to build growth and margin through an innovation reinvestment cycle—aiming to support the 2027-era competitive position. ¹⁵⁶

References

International Flavors & Fragrances Inc. (IFF) earnings transcript 2026 - Q2

Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.

IFF's Scent Recovery Driven by R&D Upgrades, 2H Growth Outlook for 2027

Sources used

Research question

Answer

Drivers of Scent recovery, 2H evolution (Fine Fragrance & Consumer Fragrance), and 2027 R&D plan

1) What are the drivers of Scent’s recovery?

A. Better R&D capability plus rebuilding the innovation pipeline

B. Volume growth and productivity improvements supporting profitability

C. Fragrance Ingredients rebound (and then normalization toward higher-value inputs)

D. Fine Fragrance execution amid Middle East uncertainty

2) How will Fine Fragrance and Consumer Fragrance evolve in the second half?

Fine Fragrance (second half trajectory)

Consumer Fragrance (second half trajectory)

Fragrance Ingredients normalization (important context for “Scent” even though not asked)

3) Plan for R&D to support 2027

A. Fix the pipeline quality and capability gap (already executed progress)

B. “Higher-value natural products” shift is underway and expected to build into next years (leading into 2027)

C. Reinvestment/innovation cycle as a long-term Remainco principle

D. Scent-specific leadership emphasis on R&D execution and perfumer-driven innovation

Bottom line summary

References

Keep Reading

IFF Scent Recovery Fueled by Q2 Strength, R&D Push, and 2027 Plan

Keep Reading

Keep Reading

IFF Scent Recovery Fueled by Q2 Strength, R&D Push, and 2027 Plan

IFF Scent Recovery Gains Momentum in Q2 2026, H2 Growth and 2027 R&D Plan

IFF Scent Recovery Accelerates on Fragrance Ingredients, H2 Outlook, 2027 R&D Plan

IFF Scent Recovery Gains Momentum in Q2 2026; H2 Outlook and 2027 R&D Plan

IFF Scent Recovery Driven by Consumer Fragrance, H2 Outlook, and 2027 R&D Plan

IFF Scent Recovery Driven by Fragrance Ingredients, R&D Push for 2027

IFF Scent Recovery Driven by R&D, H2 Outlook, 2027 Plan

IFF Scent Recovery Fueled by 2H Fine Fragrance Growth and 2027 R&D Push

IFF's Scent Recovery Gains Momentum as R&D Lays 2027 Roadmap and 2H 2026 Outlook

IFF Scent Recovery Driven by R&D Rebuild; Q2 2026 H2 Outlook and 2027 Plan

IFF's Scent Recovery Q2 2026 Highlights, H2 Outlook and 2027 R&D Plan

IFF Guides Capex at 5–6% and R&D at 8–9% Post-Divestiture Growth